Last reviewed · How we verify
ropinirole/L-dopa
ropinirole/L-dopa is a Dopamine agonist and dopamine precursor combination Small molecule drug developed by GlaxoSmithKline. It is currently FDA-approved for Parkinson's disease.
Ropinirole is a dopamine D2/D3 receptor agonist that mimics dopamine signaling, while L-dopa is a dopamine precursor that increases dopamine levels in the brain.
Ropinirole is a small molecule that acts as a D2-like dopamine receptor agonist. It is used to treat conditions such as Parkinson's disease and dyskinesias, often in combination with L-dopa.
At a glance
| Generic name | ropinirole/L-dopa |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Dopamine agonist and dopamine precursor combination |
| Target | Dopamine D2/D3 receptors (ropinirole); dopamine synthesis pathway (L-dopa) |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
This combination targets Parkinson's disease by dual mechanisms: ropinirole directly activates dopamine receptors to compensate for dopamine loss, while L-dopa (levodopa) is converted to dopamine in the brain to further restore dopaminergic neurotransmission. The combination provides complementary dopaminergic replacement therapy to alleviate motor symptoms of Parkinson's disease.
Approved indications
- Parkinson's disease
Common side effects
- Nausea
- Dizziness
- Dyskinesia
- Orthostatic hypotension
- Hallucinations
- Somnolence
Key clinical trials
- Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole (PHASE1, PHASE2)
- A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole PR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-Dopa (PHASE3)
- A Fixed Dose Study of Ropinirole Prolonged Release as Adjunctive Treatment in Patients With Advanced Parkinson's Disease (PHASE4)
- A Comparison of Ropinirole Immediate Release With Ropinirole Prolonged Release in Patients With Advanced Parkinson's (PHASE3)
- Investigational Parkinson's Disease In Patients Not Well Controlled On L-dopa (PHASE3)
- Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's (PHASE3)
- Clinical Evaluation of Ropinirole Prolonged Release/Extended Release (PR/XR) Tablet for Adjunctive Therapy to L-dopa in Subjects With Advanced Parkinson's Disease (PHASE3)
- A Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ropinirole/L-dopa CI brief — competitive landscape report
- ropinirole/L-dopa updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about ropinirole/L-dopa
What is ropinirole/L-dopa?
How does ropinirole/L-dopa work?
What is ropinirole/L-dopa used for?
Who makes ropinirole/L-dopa?
What drug class is ropinirole/L-dopa in?
What development phase is ropinirole/L-dopa in?
What are the side effects of ropinirole/L-dopa?
What does ropinirole/L-dopa target?
Related
- Drug class: All Dopamine agonist and dopamine precursor combination drugs
- Target: All drugs targeting Dopamine D2/D3 receptors (ropinirole); dopamine synthesis pathway (L-dopa)
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Neurology
- Indication: Drugs for Parkinson's disease
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing